Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to demonstrate bioequivalence of a newly developed fixed dose
combination (FDC) tablet containing linagliptin and metformin extended release compared to
the free combination of linagliptin and metformin extended release.